Two studies that together included approximately 90 recurrent glioblastoma patients treated with bevacizumab plus irinotecan demonstrated that a decreased plasma protein level of VEGF, measured, respectively, eight weeks and 15 days after the start of the treatment, was associated with improved PFS and OS [46, 165]. The gene discussed is VEGFA; the disease is glioblastoma.